Back
Compare AU
Compare GRNV vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the VanEck MSCI Australian Sustainable Equity ETF (GRNV) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
GRNV | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 627 | 78 |
Median incremental investment | $705.17 | $678.72 |
Median investment frequency | Quarterly | Monthly |
Median total investment | $1,686.46 | $2,330.51 |
Average age group | > 35 | > 35 |
Key Summary
GRNV | CURE | |
|---|---|---|
Strategy | GRNV.AX was created on 2016-04-27 by VanEck. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 252.01m in AUM and 83 holdings. GRNV.AX gives investors access to a diversified portfolio of sustainable Australian companies selected on the basis of in-depth analysis by world leading research agency MSCI ESG Research. GRNV.AX aims to provide investment returns, before fees and other costs, which track the performance of the Index. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 51.24m in AUM and 148 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | CSL Ltd (5.26 %) Westpac Banking Corp (5.09 %) Commonwealth Bank of Australia (5.01 %) | Moderna Inc (2.93 %) Twist Bioscience Corp (1.71 %) Halozyme Therapeutics Inc (1.45 %) |
Top 3 industries | Financials (43.98 %) Industrials (18.56 %) Real Estate (12.17 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | Australia (100.00 %) | United States (96.62 %) United Kingdom of Great Britain and Northern Ireland (1.35 %) Switzerland (1.13 %) |
Management fee | 0.35 % | 0.45 % |
Key Summary
GRNV | CURE | |
|---|---|---|
Issuer | VanEck | Global X |
Tracking index | MSCI Australia IMI Select SRI Screened Index - AUD | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.35 % | 0.45 % |
Price | $31.45 | $76.41 |
Size | $252.219 million | $50.449 million |
10Y return | 28.95 % | N/A |
Annual distribution yield (5Y) | 3.39 % | 0.03 % |
Market | ASX | ASX |
First listed date | 02/05/2016 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
GRNV | CURE | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 627 | 78 |
Median incremental investment | $705.17 | $678.72 |
Median investment frequency | Quarterly | Monthly |
Median total investment | $1,686.46 | $2,330.51 |
Average age group | > 35 | > 35 |
Pros and Cons
GRNV | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
GRNV | CURE |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Lower price growth | Higher price growth |
Higher distribution yield | Lower distribution yield |